NASCET


Also found in: Acronyms.

NASCET

Cardiology A clinical trial–North American Symptomatic Carotid Endarterectomy Trial designed to compare the outcomes of surgery plus medical therapy with medical therapy alone in Pts at risk for TIAs and CVAs. See Stroke, Transient ischemic attack.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
Although CREST results are not available yet, preliminary 30-day stroke and death rate of CAS arm in lead-in phase are comparable with two well-known CEA trials, namely, the NASCET and European Carotid Surgery Trial (Hobson et al., 2004).
NASCET also showed that maximal stroke-free benefit for 70-99% stenosis at 5 years was 8.9% in the surgical group, as opposed to 28.3% in the medical group.
Uzun yillar profilaktik olarak antiagregan ilaclarla tedavi yapilirken 1991 yilinda NASCET ve ECST calismalarinda KEA'nin semptomatik olgularda iskemik felc riskini medikal tedaviye gore sirasiyla %65 ve %83 oraninda azalttigi gosterilmistir.
In NASCET, there was a 9% combined incidence of infection and bleeding, and an 8.5% risk of cranial nerve palsy.
The authors of this study examined data from the North American Symptomatic Carotid Endarterectomy Trial (NASCET) on patients from 1988 to 1997 with unilateral symptomatic carotid stenosis and asymptomatic contralateral stenosis.
The rate of perioperative complication was comparable to that of the North American Symptomatic Carotid Endarterectomy Trial (NASCET) in which carotid endarterectomy was found to be more effective than medical therapy for individuals with high grade ([greater than]70 percent) symptomatic carotid artery disease (North American Symptomatic Carotid Endarterectomy Trial Collaborators 1991).
The degree of stenosis was determined by duplex ultrasonography (DUS) according to the NASCET criteria using 5MHz linear transducer.
Additional exclusion criteria were severe cognitive impairment (MMSE < 10), severe aphasia, blood pressure (BP) persistently higher then 160/100 mmHg or lower than 90/60 mmHg, internal carotid artery stenosis > 60% by NASCET criteria, severe cardiac disease, intracardiac thrombus, severe medical conditions, contractures of lower extremities, thrombophlebitis, and lower extremity deep vein thrombosis.
Diferentes estudios como NASCET (The North American Symptomatic Carotid Endarterectomy Trial--Ensayo de Endarterectomia Carotidea Sintomatica de Norte America), ECST (European Carotid Surgery Trial Ensayo Europeo de Cirugia de Carotida), y el Programa de Estudio Cooperativo de Asuntos de los Veteranos (Veterans Affairs Cooperative Study Program), fueron fundamentales para demostrar la efectividad de la revascularizacion quirurgica en el tratamiento de la enfermedad carotidea oclusiva sintomatica.
All of the patients were symptomatic (with amaurosis fugax, a transient ischemic attack, or a stroke within the previous 180 days) and also had at least 50% stenosis in their carotid artery based on the criteria of the North American Symptomatic Carotid Endarterectomy Trial (NASCET).
Background The North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST), both reported in 1991, showed the striking clinical benefit of surgery over drug therapy for patients with symptomatic carotid stenoses [is less than] 70%.[1,2] These studies also clearly demonstrated the lack of benefit of carotid endarterectomy (CEA) for patients with mild lesions (0% to 29%).